Sahin Gozde, Bakirci Isil Turan, Sozen Isik, Kilic Sinem Ozsahin, Afsar Selim, Kocadal Nilufer Cetinkaya, Geyikoglu Ipek
Division of Gynaecologic Oncology, Department of Obstetrics and Gynecology, Basaksehir Cam and Sakura City Hospital, Istanbul, Turkey.
Division of Perinatology, Department of Obstetrics and Gynecology, Basaksehir Cam and Sakura City Hospital, Istanbul, Turkey.
Arch Gynecol Obstet. 2025 Apr 16. doi: 10.1007/s00404-025-08023-5.
Adenomyosis is a gynecological condition that frequently coexists with gynecological malignancies and has been shown to influence disease outcomes. However, its impact on ovarian cancer prognosis remains unclear. This study aimed to investigate the relationship between adenomyosis and clinicopathological and prognostic features in ovarian cancer patients.
We retrospectively analyzed 226 patients with ovarian cancer who underwent surgery between 2020 and 2023. The patients were divided into two groups based on the presence (n = 114) or absence (n = 112) of adenomyosis, confirmed by histopathological examination. Clinicopathological characteristics, including histological subtypes, disease-free survival (DFS), and overall survival (OS) were compared between the groups with a median follow-up of 36 months.
Patients with adenomyosis demonstrated more favorable characteristics, including early stage disease (54.3% vs 39.2%, p = 0.048), lower-grade tumors (55.2% vs 31.2%, p = 0.049), and smaller tumor sizes (39.4% vs 26.7%, p = 0.043). Adenomyosis was significantly associated with endometrioid subtype (OR = 2.89, p = 0.043) and negatively associated with serous carcinoma (OR = 0.39, p = 0.034). Three-year DFS was significantly better in the adenomyosis group (79.2% vs 73.9%, p = 0.01), particularly in high-grade tumors (80% vs 58%, p < 0.05). No significant difference was observed in overall OS (73.3% vs 73.1%, p = 0.14), although high-grade tumors with adenomyosis showed improved OS (71% vs 57%, p < 0.05).
The presence of adenomyosis in patients with ovarian cancer was associated with favorable clinicopathological features, particularly endometrioid histology and low-grade tumors, and improved survival in high-grade tumors. These findings suggest a potential biological interaction between adenomyosis and ovarian cancer that warrants further investigation for personalized treatment approaches.
子宫腺肌病是一种妇科疾病，常与妇科恶性肿瘤并存，且已被证明会影响疾病的预后。然而，其对卵巢癌预后的影响仍不明确。本研究旨在探讨子宫腺肌病与卵巢癌患者临床病理特征及预后特征之间的关系。
我们回顾性分析了2020年至2023年间接受手术的226例卵巢癌患者。根据组织病理学检查确诊的子宫腺肌病的有无，将患者分为两组（存在子宫腺肌病组，n = 114；不存在子宫腺肌病组，n = 112）。比较两组患者的临床病理特征，包括组织学亚型、无病生存期（DFS）和总生存期（OS），中位随访时间为36个月。
患有子宫腺肌病的患者表现出更有利的特征，包括疾病早期（54.3%对39.2%，p = 0.048）、低级别肿瘤（55.2%对31.2%，p = 0.049）和较小的肿瘤大小（39.4%对26.7%，p = 0.043）。子宫腺肌病与子宫内膜样亚型显著相关（OR = 2.89，p = 0.043），与浆液性癌呈负相关（OR = 0.39，p = 0.034）。子宫腺肌病组的三年DFS显著更好（79.2%对73.9%，p = 0.01），尤其是在高级别肿瘤中（80%对58%，p < 0.05）。总体OS未观察到显著差异（73.3%对73.1%，p = 0.14），尽管患有子宫腺肌病的高级别肿瘤的OS有所改善（71%对57%，p < 0.05）。
卵巢癌患者中子宫腺肌病的存在与有利的临床病理特征相关，特别是子宫内膜样组织学和低级别肿瘤，并改善了高级别肿瘤的生存率。这些发现提示子宫腺肌病与卵巢癌之间可能存在生物学相互作用，值得进一步研究以制定个性化治疗方案。
Zotero 插件